JOHN L. ABRUZZO, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
A burgeoning market for drugs generally classed as anti-rheumatic (or anti-inflammatory) and a clear need for drugs able to reduce the joint destruction caused by rheumatoid arthritis have led to intense efforts in drug development. Where we stand in these efforts was reviewed at a forum on the treatment of inflammatory connective tissues held by the American Society for Clinical Pharmacology and Therapeutics at its 79th Annual Meeting in Atlanta, 29-31 March 1978.
More than 50 active anti-rheumatic compounds are under investigation. Most of these are drugs classified as arylalkanoic acid derivatives—aspirin, other types of salicylates, indomethacin, and phenylbutazone are
ABRUZZO JL. Newer Anti-Rheumatic Drugs. Ann Intern Med. 1978;89:131–132. doi: https://doi.org/10.7326/0003-4819-89-1-131
Download citation file:
Published: Ann Intern Med. 1978;89(1):131-132.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use